Article Text

Download PDFPDF
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib
  1. Nicole K Yun1,
  2. Taha Alrifai2,
  3. Ira J Miller3 and
  4. Melissa L Larson2
  1. 1Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
  2. 2Division of Hematology, Oncology, and Stem Cell Transplant, Rush University Medical Center, Chicago, Illinois, USA
  3. 3Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA
  1. Correspondence to Dr Nicole K Yun; nicole_k_yun{at}rush.edu

Abstract

We present a unique case of a patient with a long-standing history of indolent chronic lymphocytic leukaemia (CLL) who suddenly developed autoimmune haemolytic anaemia after starting immune checkpoint inhibitor therapy for bladder cancer. He had no clear indication to start CLL-directed treatment based on current clinical practice guidelines; however, targeted treatment of CLL with ibrutinib proved to be effective in treating the haemolytic anaemia.

  • haematology (drugs and medicines)
  • haematology (incl blood transfusion)
  • malignant and benign haematology

Statistics from Altmetric.com

Footnotes

  • Contributors The corresponding author, NKY, was the the primary writer of the manuscript with significant assistance from TA, IJM and MLL. All authors approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.